Breakthrough Discovery at NTU Singapore
Researchers at Nanyang Technological University (NTU) Singapore's Lee Kong Chian School of Medicine have uncovered a significant finding in the fight against Parkinson's disease. Their study reveals that a fat-producing enzyme known as glycerol-3-phosphate acyltransferase, or GPAT, plays a crucial role in worsening brain cell damage. Specifically, the mitochondrial isoform of GPAT exacerbates the toxic effects of α-synuclein, the protein that clumps in the brains of Parkinson's patients, leading to accelerated neurodegeneration.
This discovery highlights how disruptions in lipid metabolism within brain cells can amplify disease progression. By targeting GPAT, scientists hope to develop novel therapies that could slow or halt the devastating impacts of Parkinson's, a condition affecting motor functions and quality of life for millions worldwide.
Understanding Parkinson's Disease in Singapore Context
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the substantia nigra region of the brain. Symptoms include tremors, rigidity, bradykinesia (slowness of movement), and postural instability. In Singapore, PD is the second most common neurodegenerative disease, affecting approximately 0.3% of residents aged 50 and above, or about three in every 1,000 individuals in that age group. With an aging population, the prevalence is expected to rise, placing greater strain on healthcare systems and underscoring the urgency for local research breakthroughs like this one from NTU.
Globally, PD impacts over 10 million people, with incidence rates climbing due to increased life expectancy. The lack of a cure makes studies like NTU's vital, particularly as they explore modifiable pathways such as lipid processing in neurons and glial cells.
The GPAT Enzyme: A Key Player in Lipid Metabolism
Glycerol-3-phosphate acyltransferase (GPAT) is the first enzyme in the triglyceride synthesis pathway, catalyzing the acylation of glycerol-3-phosphate to form lysophosphatidic acid. This step is essential for fat storage but, in the context of PD, becomes detrimental. The mitochondrial form of GPAT, identified in the NTU study through its Drosophila homolog mino, disrupts cellular homeostasis by promoting excessive lipid peroxidation—a process where reactive oxygen species (ROS) oxidize lipids in cell membranes, leading to chain reactions that damage proteins, DNA, and organelles.
In healthy cells, balanced lipid metabolism supports membrane integrity and energy production. However, in PD, α-synuclein aggregates interfere with this balance, and GPAT hyperactivity compounds the issue by overloading mitochondria—the cell's powerhouses—with lipids, impairing ATP production and heightening oxidative stress.
Methodology: From Fruit Flies to Mouse Models
The NTU team employed a multi-model approach to pinpoint GPAT's role. Using Drosophila melanogaster (fruit flies) engineered to overexpress human α-synuclein, researchers screened for genetic modifiers of toxicity. Knocking down mino (Drosophila GPAT) significantly rescued dopaminergic neuron loss and improved motor function.
- Fruit fly models allowed rapid genetic screening of lipid metabolism genes.
- Mouse primary neurons and iPSC-derived models confirmed increased lipid peroxidation upon GPAT overexpression.
- Pharmacological inhibition with compounds like FSG67 mimicked genetic knockdown, reducing α-synuclein aggregation and ROS levels.
These stepwise validations—from invertebrate screens to mammalian cells—provide robust evidence, bridging basic science to potential therapeutics.
Key Findings: The 'Double Hit' Mechanism
The study demonstrates GPAT's dual destructive action:
- Mitochondrial Impairment: GPAT boosts lipid droplet formation in mitochondria, starving them of substrates for energy and triggering dysfunction.
- Lipid Peroxidation Surge: Excess lipids fuel peroxidation chains, amplifying α-synuclein fibril formation and propagation.
Reducing GPAT activity halved neuron loss in models, suggesting it as a druggable target. The paper, published in Nature Communications, details how GPAT links lipid dysregulation to PD hallmarks.
Spotlight on NTU Researchers
Leading the effort is Professor Lim Kah Leong, a renowned Parkinson's expert at NTU LKCMedicine and Associate Vice President of Research (Biomedical and Life Sciences). Prof Lim's lab focuses on molecular mechanisms of neurodegeneration, with prior discoveries including PD risk genes in Asians. Co-first author Mengda Ren and the team leveraged NTU's advanced facilities for this interdisciplinary work.
Prof Lim notes, "This reveals how fat metabolism influences α-synuclein toxicity, opening new treatment avenues for Parkinson's." Their work builds on NTU's strong neuroscience portfolio.
NTU's Excellence in Neuroscience Research
NTU Singapore stands at the forefront of biomedical innovation, with LKCMedicine pioneering translational neuroscience. Recent feats include identifying SMPD1 as an East Asian PD risk gene and molecular pairs for neuroprotection. NTU's investment in labs like the Neurodegeneration Research Laboratory fosters collaborations with NNI and global partners.
Singapore's Research, Innovation and Enterprise 2025 plan bolsters such efforts, positioning NTU as a hub for PD research careers.
Singapore's Vibrant Parkinson's Research Ecosystem
Beyond NTU, Duke-NUS maps brainstem development for PD therapies, while NUS and NNI advance biomarkers. Joint initiatives like the Sydney-Singapore AI brain models accelerate discoveries. Government funding via NMRC supports over 50 PD projects, making Singapore a leader in Asian neurodegeneration research.
For more on the study, visit the NTU press release or the full paper in Nature Communications.
Global Insights: Lipids and α-Synuclein
Lipid metabolism's role in PD is gaining traction. Prior studies link monounsaturated fatty acids and stearoyl-CoA desaturase to α-synuclein aggregation. GPAT inhibition aligns with ferroptosis blockers like ACSL4 inhibitors, suggesting shared pathways.
NTU's work extends these, emphasizing mitochondrial lipids.
Therapeutic Horizons and Challenges
Inhibiting GPAT could complement levodopa therapy. Existing GPAT blockers for obesity (e.g., FSG67 analogs) may repurpose for PD, pending safety trials. Challenges include brain penetration and isoform specificity to avoid metabolic side effects.
- Short-term: Validate in human iPSCs and primates.
- Long-term: Clinical trials targeting lipid peroxidation.
Singapore's clinical trial infrastructure positions NTU well.
Future Outlook for PD Research in Singapore
With rising PD cases (projected 76% global increase by 2050), NTU's GPAT study heralds precision medicine. Integrating AI, genomics, and lipidomics promises faster translations. For aspiring researchers, Singapore offers PhD programs and postdocs at NTU.
Careers in Neuroscience at Singapore Universities
NTU and peers seek experts in neurodegeneration. Roles in lipid biology and PD modeling abound, with competitive salaries and grants. Explore opportunities to contribute to breakthroughs like this GPAT discovery.
